Enzo Biochem, Inc. (ENZ)
NYSE: ENZ · IEX Real-Time Price · USD
1.155
-0.015 (-1.28%)
Jul 16, 2024, 12:13 PM EDT - Market open

Company Description

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.

The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.

The company’s proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.

It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Enzo Biochem, Inc.
Enzo Biochem logo
Country United States
Founded 1976
Industry Diagnostics & Research
Sector Healthcare
Employees 179
CEO Ms. Kara Cannon

Contact Details

Address:
60 Executive Blvd
Farmingdale, New York 11735
United States
Phone (516) 755-5500
Website enzo.com

Stock Details

Ticker Symbol ENZ
Exchange NYSE
Fiscal Year August - July
Reporting Currency USD
CIK Code 0000316253
CUSIP Number 294100102
ISIN Number US2941001024
Employer ID 13-2866202
SIC Code 8071

Key Executives

Name Position
Kara Cannon Chief Executive Officer
Patricia Eckert CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Jun 26, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 13, 2024 10-Q Quarterly Report
May 24, 2024 8-K Current Report
Mar 13, 2024 8-K Current Report
Mar 13, 2024 10-Q Quarterly Report
Feb 27, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 8-K Current Report
Dec 21, 2023 DEFR14A Filing